Astorg

📣 𝗔𝘀𝘁𝗼𝗿𝗴 𝗣𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 𝗖𝗼𝗺𝗽𝗮𝗻𝘆 𝗡𝗲𝘄𝘀 We’re pleased to share the latest milestone in our partnership with IQ-EQ, as the firm continues to build its global leadership in investor services.   IQ-EQ has signed an agreement to acquire AMAL, a market leader in corporate trust, agency services, and loan servicing in Australia and New Zealand, managing over A$37 billion in assets across the region.   With this acquisition, IQ-EQ expands its integrated offering into a key new geography, reinforcing its position as the partner of choice for private markets investors worldwide.   Since first acquiring IQ-EQ in 2016, Astorg has supported the firm’s growth journey, further cementing its position as a global category leader in the investor services space. In 2022, Astorg raised a $1.3 billion continuation fund to provide additional capital to continue supporting the firm’s ambitious growth plans.    🎙️Francois de Mitry, Chief Investment Officer at Astorg: “Our decade-long partnership with IQ-EQ has been defined by a shared commitment to excellence and ambition. The acquisition of the AMAL Group marks a further next step in the firm’s global expansion strategy - extending its footprint into Australia and New Zealand and further reinforcing its position as the leading global partner to private markets investors. We remain committed to supporting IQ-EQ’s long-term growth strategy.” 👇 To read the full 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲, please follow the link below. #Acquisition #ValueCreation #Partnership #Growth #BusinessExpansion #InvestorServices https://lnkd.in/effCjERk

🚀 𝗨𝗻𝘃𝗲𝗶𝗹𝗶𝗻𝗴 𝗡𝗲𝘅𝗽𝗿𝗶𝗻𝗴 𝗛𝗲𝗮𝗹𝘁𝗵 We’re proud to launch today Nexpring Health, the new brand identity of Astorg’s global MedTech company dedicated to advancing reproductive health and Assisted Reproductive Technology (ART).   🎯 Nexpring Health is the result of 𝗔𝘀𝘁𝗼𝗿𝗴’𝘀 𝗹𝗼𝗻𝗴-𝘁𝗲𝗿𝗺 𝘃𝗶𝘀𝗶𝗼𝗻 𝗮𝗻𝗱 𝗯𝗼𝗹𝗱, 𝗰𝗿𝗲𝗮𝘁𝗶𝘃𝗲 𝗱𝗲𝗮𝗹𝗺𝗮𝗸𝗶𝗻𝗴 - bringing together the strengths of Hamilton Thorne, Cook Medical’s Reproductive Health business, and FUJIFILM Irvine Scientific’s Medical Media division - under a common brand identity and integrated offering.   “With Astorg’s support, Nexpring Health is uniting decades of innovation and expertise to serve a clear vision and purpose: to remove complexity and build a comprehensive ecosystem of solutions that meets the full range of needs of the professionals at the heart of fertility clinics -embryologists and clinicians” – said Wil Boren, 𝗖𝗘𝗢, 𝗼𝗳 𝗡𝗲𝘅𝗽𝗿𝗶𝗻𝗴 𝗛𝗲𝗮𝗹𝘁𝗵.   “As a long-term partner to Nexpring Health, we are committed to supporting its growth journey and helping deliver meaningful impact for professionals and patients around the world” – continued Judith Charpentier, 𝗖𝗼-𝗛𝗲𝗮𝗱 𝗼𝗳 𝗙𝗹𝗮𝗴𝘀𝗵𝗶𝗽 𝗙𝘂𝗻𝗱 𝗮𝗻𝗱 𝗛𝗲𝗮𝗱 𝗼𝗳 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗮𝘁 𝗔𝘀𝘁𝗼𝗿𝗴.   🎙️Olivier Lieven, Partner and Tobias Nordblom, Managing Director, Astorg, added: “We look forward to continuing our close collaboration with Nexpring Health, building on a strong foundation and a uniquely positioned platform to support ART professionals by providing high-quality solutions and trusted service, and ultimately advance reproductive care”   👏 A warm welcome to thomas axelsson as Non-executive Chairman, and new board members John Enneking and Vivid Sehgal - bringing decades of leadership across MedTech and healthcare.   👉 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲 𝗮𝗯𝗼𝘂𝘁 𝘁𝗵𝗲 𝗹𝗮𝘂𝗻𝗰𝗵: https://lnkd.in/eBbViM7c   #NexpringHealth #ReproductiveHealth #ART #MedTech #FertilityCare #HealthcareInnovation #BusinessExpansion #Partnership #Growth #CreativeDealMaking

📣 𝗔𝘀𝘁𝗼𝗿𝗴 𝗣𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 𝗖𝗼𝗺𝗽𝗮𝗻𝘆 𝗡𝗲𝘄𝘀 Astorg is pleased to share that its portfolio company, Steliau Technology, a leading provider of value-added electronic solutions, has acquired UX Gruppe, a German electronic solutions specialist serving a broad range of industries with innovative, tailored solutions. This 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗮𝗰𝗾𝘂𝗶𝘀𝗶𝘁𝗶𝗼𝗻 𝗺𝗮𝗿𝗸𝘀 𝗮 𝘀𝗶𝗴𝗻𝗶𝗳𝗶𝗰𝗮𝗻𝘁 𝗺𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲 𝗶𝗻 𝗦𝘁𝗲𝗹𝗶𝗮𝘂’𝘀 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗲𝘅𝗽𝗮𝗻𝘀𝗶𝗼𝗻, 𝗿𝗲𝗶𝗻𝗳𝗼𝗿𝗰𝗶𝗻𝗴 𝗶𝘁𝘀 𝗽𝗼𝘀𝗶𝘁𝗶𝗼𝗻 𝗮𝘀 𝘁𝗵𝗲 𝗹𝗲𝗮𝗱𝗶𝗻𝗴 𝗽𝗮𝗻-𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗽𝗮𝗿𝘁𝗻𝗲𝗿 𝗳𝗼𝗿 𝗰𝘂𝘀𝘁𝗼𝗺𝗶𝘇𝗲𝗱 𝗲𝗹𝗲𝗰𝘁𝗿𝗼𝗻𝗶𝗰 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀. By integrating UX Gruppe’s deep expertise in HMI solutions, embedded software, and hardware engineering, Steliau strengthens its capabilities across the entire product lifecycle - from design and engineering to system integration and supply chain management. 🎙️PASCAL REYNOUD, 𝗖𝗘𝗢 𝗼𝗳 𝗦𝘁𝗲𝗹𝗶𝗮𝘂 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝗚𝗿𝗼𝘂𝗽: "The acquisition of UX Gruppe cements our position as a leading pan-European partner for electronic solutions. Their advanced design expertise perfectly complements our value-added distribution model, allowing us to support customers from project inception to full-scale industrialization across Europe." Since being acquired by Astorg in 2024, Steliau has accelerated its growth strategy through targeted acquisitions. With Astorg’s backing, the company continues to solidify its leadership and drive value-added innovation for customers across Europe. 👇 To read the full 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲, follow the link below

🌍 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗣𝗿𝗶𝘃𝗮𝘁𝗲 𝗖𝗮𝗽𝗶𝘁𝗮𝗹 𝗦𝘂𝗺𝗺𝗶𝘁 | 𝗟𝗼𝗻𝗱𝗼𝗻 Astorg attended the European Private Capital Summit this week in London, hosted by the CapLink Group, and gathering 350+ industry experts and leading investors, to discuss the evolving private equity landscape. Valerie Legat, 𝗛𝗲𝗮𝗱 𝗼𝗳 𝗗𝗶𝗴𝗶𝘁𝗮𝗹 𝗮𝘁 𝗔𝘀𝘁𝗼𝗿𝗴, took part in a 𝗽𝗮𝗻𝗲𝗹 𝗱𝗶𝘀𝗰𝘂𝘀𝘀𝗶𝗼𝗻 alongside industry peers - Dominic Gallello (Bridgepoint), Fang Fang (Apax), Maxime Jacquot (Gain.pro) – to explore 𝗵𝗼𝘄 𝗽𝗿𝗶𝘃𝗮𝘁𝗲 𝗰𝗮𝗽𝗶𝘁𝗮𝗹 𝗳𝗶𝗿𝗺𝘀 𝗮𝗿𝗲 𝗹𝗲𝘃𝗲𝗿𝗮𝗴𝗶𝗻𝗴 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝘃𝗲 𝗔𝗜 𝘁𝗼 𝗱𝗿𝗶𝘃𝗲 𝘃𝗮𝗹𝘂𝗲 𝗰𝗿𝗲𝗮𝘁𝗶𝗼𝗻. 🎤 Valerie Legat: “At Astorg, we leverage GenAI to drive operational excellence and revenue growth across our portfolio. It’s not about chasing a silver bullet - it’s about executing a structured, pragmatic strategy. We bring together our digital leaders, invest in strong foundations, and forge key partnerships with top tech players. Success comes from a ‘Day 1’ mindset - staying agile, sharp, and ready to adapt as the landscape evolves." AI is reshaping private equity, and we are committed to supporting our portfolio companies in their value creation plan and transformation journey. #EuropeanPrivateCapitalSummit #GenerativeAI #DigitalTransformation #ValueCreation #Leadership

📣 𝗔𝘀𝘁𝗼𝗿𝗴 𝗣𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 𝗖𝗼𝗺𝗽𝗮𝗻𝘆 𝗡𝗲𝘄𝘀 Astorg is pleased to share that its portfolio company, Lebronze alloys (LBA), a global leader in advanced materials, acquires two companies: 🎯Allied Copper Alloys Ltd (ACA), a leading UK-based service center specializing in high-performance copper alloys. 🎯AW Fraser Ltd, a world-class alloy producer based in New Zealand, recognized for its expertise in high-quality manufacturing. 𝗧𝗵𝗲𝘀𝗲 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗮𝗰𝗾𝘂𝗶𝘀𝗶𝘁𝗶𝗼𝗻𝘀 𝗺𝗮𝗿𝗸 𝗮𝗻 𝗶𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝘁 𝗺𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲 𝗶𝗻 𝗟𝗕𝗔’𝘀 𝗴𝗹𝗼𝗯𝗮𝗹 𝗲𝘅𝗽𝗮𝗻𝘀𝗶𝗼𝗻 𝗮𝗻𝗱 𝗴𝗿𝗼𝘄𝘁𝗵 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝘆. 🎙️ Michel Dumont, 𝗣𝗿𝗲𝘀𝗶𝗱𝗲𝗻𝘁 𝗼𝗳 𝗟𝗲𝗯𝗿𝗼𝗻𝘇𝗲 𝗔𝗹𝗹𝗼𝘆𝘀: “With ACA and AW Fraser, we are integrating two well-established companies with strong local presence in growing markets. This strategic move enhances our global service network and expands our industrial capabilities and product portfolio. It is fully aligned with our mission as one of the leaders of specialty alloys.” Astorg acquired LBA in 2024 to accelerate the execution of its ambitious growth plans, notably through targeted acquisitions. With Astorg’ backing, LBA continues to expand its global footprint, further strengthens its industry leadership, with a strong commitment to quality, innovation, and operational excellence. 👇 To read the full 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲, follow the link below #AdvancedMaterials#Manufacturing#Metallurgy#CopperAlloys#StrategicExpansion#Growth

📣 𝗔𝘀𝘁𝗼𝗿𝗴 𝗣𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 𝗖𝗼𝗺𝗽𝗮𝗻𝘆 𝗡𝗲𝘄𝘀   Astorg is pleased to share that its portfolio company Corden Pharma - A Full-Service CDMO, a global leader in peptide-based drug manufacturing, 𝗵𝗮𝘀 𝘀𝗶𝗴𝗻𝗲𝗱 𝗮 𝗹𝗼𝗻𝗴-𝘁𝗲𝗿𝗺 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽 𝘄𝗶𝘁𝗵 Viking Therapeutics, Inc. (Nasdaq: VKTX) 𝘁𝗼 𝘀𝘂𝗽𝗽𝗼𝗿𝘁 𝘁𝗵𝗲 𝗰𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹 𝘀𝘂𝗽𝗽𝗹𝘆 𝗼𝗳 𝗩𝗞𝟮𝟳𝟯𝟱, 𝗮 𝗻𝗲𝘅𝘁-𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗚𝗟𝗣-𝟭 𝗱𝗿𝘂𝗴 𝗰𝗮𝗻𝗱𝗶𝗱𝗮𝘁𝗲. Viking Therapeutics is a clinical-stage company focused on developing novel therapies for metabolic and endocrine disorders. This long-term partnership means CordenPharma will leverage its fully integrated supply chain to support Viking Therapeutics by providing: ✅ Manufacturing of the active ingredient for VK2735, a next-generation GLP-1 drug ✅ Production of the injectable version through its fill-finish services ✅ Manufacturing of the oral tablet formulation 🎙️Dr Michael Quirmbach, 𝗣𝗿𝗲𝘀𝗶𝗱𝗲𝗻𝘁 & 𝗖𝗘𝗢, 𝗖𝗼𝗿𝗱𝗲𝗻𝗣𝗵𝗮𝗿𝗺𝗮: "We are proud to support Viking Therapeutics with an end-to-end solution for their innovative VK2735 drug candidate. This partnership highlights CordenPharma’s unique ability to integrate large-scale peptide drug substance production with advanced sterile injectable and oral solid dosage manufacturing. Our teams are committed to ensuring a secure and seamless supply chain to meet the increasing demand for GLP-1 peptide therapeutics and improve patient outcomes." CordenPharma was acquired by Astorg in 2022 to accelerate its development and further strengthen its leadership in the CDMO peptide space. With Astorg’s backing, the company continues to expand its capabilities and drive innovation in complex drug manufacturing. 👇 To read the full 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲, follow the link below #Pharma#BioTech#MedTech#GPL1#Investment#Transformation#Manufacturing #Growth #BusinessExpansion

📣 𝗔𝘀𝘁𝗼𝗿𝗴 𝗣𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 𝗖𝗼𝗺𝗽𝗮𝗻𝘆 𝗡𝗲𝘄𝘀 Astorg is pleased to share that its portfolio company - Corden Pharma - A Full-Service CDMO - is expanding its Peptide Platform with a €500m investment in a greenfield facility construction in the Basel region of Switzerland. This leading pharma and biotech hub in Europe, will deliver flexible and efficient peptide manufacturing to meet the growing demand of innovative peptide medicines for CordenPharma’s customers and patients. This investment is in parallel with ongoing expansions and additional greenfield capacity at CordenPharma Colorado – both developments significantly enhancing the company’s production capabilities. 🎙️Judith Charpentier, 𝗖𝗼-𝗛𝗲𝗮𝗱 𝗼𝗳 𝗙𝗹𝗮𝗴𝘀𝗵𝗶𝗽 𝗙𝘂𝗻𝗱 𝗮𝗻𝗱 𝗛𝗲𝗮𝗱 𝗼𝗳 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲: “CordenPharma’s bold expansion reflects its leadership in addressing the growing demand for peptide manufacturing. As a long-term investor, we are fully committed to supporting this growth, combining industrial excellence with strategic investment to strengthen CordenPharma’s position as a leading global CDMO. Ultimately, this expansion contributes to expanding access to those life-saving peptide-based medicines for patients.” CordenPharma was first acquired by Astorg in 2022 to accelerate its development plans. With Astorg’s backing and these expansions, the company is well-positioned to execute its growth strategy. 👇 To read the full 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲 please follow the link below. https://lnkd.in/ek2ygNiQ #Pharma #BioTech #MedTech #Investment #Transformation#Manufacturing #Growth #BusinessExpansion

📣 𝗔𝘀𝘁𝗼𝗿𝗴 𝗣𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 𝗖𝗼𝗺𝗽𝗮𝗻𝘆 𝗡𝗲𝘄𝘀   Astorg is pleased to share that its portfolio company IQ-EQ has successfully completed the acquisition of Agama Group – a market-leading independent regulatory compliance firm based in France and Luxembourg.    This strategic acquisition significantly enhances IQ-EQ’s global regulatory compliance offering, further solidifying its position as a comprehensive "one-stop shop" for fund and asset managers in France. With an already robust suite of services - including fund administration, outsourced CFO, valuation, risk management, and third-party AIFM solutions - IQ-EQ is now even better positioned to support its clients with world-class regulatory expertise.   Astorg is thrilled to continue to support IQ-EQ, a global, top-tier investor services group with an unrivalled offering to meet the administration, compliance, and reporting needs of the investment sector in full and worldwide. 👇 To read the full 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲, please follow the link below. #oneiqeq #privateequity #pere #fundadministration #investorservices #RegulatoryCompliance #partnership #growth   Mark Pesco, Serge Krancenblum, Diana Senanayake, Philippe LEVREL, Louis Grégoire Logre, Jean Bernard Quillon, Bertrand d'Anselme, Justin Partington, Francois de Mitry, Benjamin Cordonnier, Frederick Young and Emily Hyslop  

🚀 𝗖𝗼𝗻𝗴𝗿𝗮𝘁𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀 𝘁𝗼 𝗼𝘂𝗿 𝟮𝟬𝟮𝟱 𝗧𝗮𝗹𝗲𝗻𝘁 𝗣𝗿𝗼𝗺𝗼𝘁𝗶𝗼𝗻𝘀!   As we continue to elevate our next generation of leaders, 𝘄𝗲’𝗿𝗲 𝗽𝗹𝗲𝗮𝘀𝗲𝗱 𝘁𝗼 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗲 𝘁𝗵𝗲 𝗽𝗿𝗼𝗺𝗼𝘁𝗶𝗼𝗻 𝗼𝗳 Chris Cozzone and Olivier Lieven 𝘁𝗼 𝗣𝗮𝗿𝘁𝗻𝗲𝗿𝘀.   𝗖𝗵𝗿𝗶𝘀 𝗖𝗼𝘇𝘇𝗼𝗻𝗲 has been a driving force in building Astorg’s Technology platform in North America. He has significantly contributed to solidifying the firm’s reputation among key stakeholders and developing compelling value-creation opportunities, as evidenced by the high-quality assets brought to the firm with a clear right to win derived from his dedication, networks and expertise.   𝗢𝗹𝗶𝘃𝗶𝗲𝗿 𝗟𝗶𝗲𝘃𝗲𝗻 has played a crucial role in enhancing Astorg’s leadership position in the Healthcare sector, particularly within Pharma Services. His focus and sector expertise enabled him to engineer complex proprietary transactions, like the recent take-private transaction of Hamilton Thorne and the simultaneous acquisition of Cook Medical’s Reproductive Health business, followed by the add-on acquisition of FUJIFILM Irvine Scientific’s Medical Media Business. Combining these three businesses creates a new global leader in the Assisted Reproductive Technology MedTech space.   𝗔𝗱𝗱𝗶𝘁𝗶𝗼𝗻𝗮𝗹𝗹𝘆, 𝗵𝗮𝘃𝗲 𝗯𝗲𝗲𝗻 𝗽𝗿𝗼𝗺𝗼𝘁𝗲𝗱 𝘁𝗼 𝗠𝗮𝗻𝗮𝗴𝗶𝗻𝗴 𝗗𝗶𝗿𝗲𝗰𝘁𝗼𝗿𝘀:  ● Nathan Geerinck, Bastien Hermans, Daniel Müller, Chuck Sandilya - Investment team ● Alexandre Falewee, Capital Markets team ● Camille Lebargy, Human Capital team  ● Nathalie Medawar, ESG team    𝗛𝗮𝘃𝗲 𝗯𝗲𝗲𝗻 𝗽𝗿𝗼𝗺𝗼𝘁𝗲𝗱 𝘁𝗼 𝗗𝗶𝗿𝗲𝗰𝘁𝗼𝗿𝘀: ● Emily Hyslop, Louis Jouglard, Adrian Loeffler Maddie Yudkin - Investment team ● Myriel van Pampus - Finance team   𝗛𝗮𝘃𝗲 𝗯𝗲𝗲𝗻 𝗽𝗿𝗼𝗺𝗼𝘁𝗲𝗱 𝘁𝗼 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗠𝗮𝗻𝗮𝗴𝗲𝗿𝘀: ● Olivier Gourgue, Guy Holden and Clémence Kopff - Investment team   These milestones reflect our commitment to cultivating the next generation of leaders who embody our brand, culture, and dedication to creating value while serving our investors.   🎉 Join us in congratulating them all and celebrating their achievements!    𝗙𝗶𝗻𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗣𝗿𝗲𝘀𝘀 𝗥𝗲𝗹𝗲𝗮𝘀𝗲 𝗵𝗲𝗿𝗲 👉 https://lnkd.in/eACYw4uu   #AstorgLeadership #Promotions #Partnership #Talent #Growth

📰𝗣𝗿𝗲𝘀𝘀 𝗥𝗲𝗹𝗲𝗮𝘀𝗲   Following the recent completion of the 𝘁𝗮𝗸𝗲-𝗽𝗿𝗶𝘃𝗮𝘁𝗲 𝗼𝗳 The Hamilton Thorne Group, 𝗮𝗻𝗱 𝘀𝗶𝗺𝘂𝗹𝘁𝗮𝗻𝗲𝗼𝘂𝘀 𝗮𝗰𝗾𝘂𝗶𝘀𝗶𝘁𝗶𝗼𝗻 𝗼𝗳 Cook Medical’s Reproductive Health business, the newly combined global leader in Assisted Reproductive Technology has signed a definitive agreement to acquire FUJIFILM Irvine Scientific’s Medical Media Business (“Irvine Scientific MBU”) from FUJIFILM Irvine Scientific.    FUJIFILM Irvine Scientific MBU provides products including culture and vitrification media for in-vitro fertilization (IVF), infertility research, and cytogenetic analysis. Astorg is now bringing the three businesses together creating a new global leading ART MedTech company with a new brand identity for the combined businesses being rolled out this year.    🎙️𝗝𝘂𝗱𝗶𝘁𝗵 𝗖𝗵𝗮𝗿𝗽𝗲𝗻𝘁𝗶𝗲𝗿, 𝗖𝗼-𝗛𝗲𝗮𝗱 𝗼𝗳 𝗙𝗹𝗮𝗴𝘀𝗵𝗶𝗽 𝗙𝘂𝗻𝗱 𝗮𝗻𝗱 𝗛𝗲𝗮𝗱 𝗼𝗳 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲, comments: “This strategic add-on acquisition of a leading portfolio of ART media further strengthens the combined company’s ability to support fertility professionals, clinics, laboratories, and patients by delivering advanced solutions that improve fertility outcomes".    “With the combined business, we stand out as a global category leader driven by innovation and supported by high quality products”, continue 𝗢𝗹𝗶𝘃𝗶𝗲𝗿 𝗟𝗶𝗲𝘃𝗲𝗻, and 𝗧𝗼𝗯𝗶𝗮𝘀 𝗡𝗼𝗿𝗱𝗯𝗹𝗼𝗺.   👉𝗧𝗼 𝗿𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲, 𝗳𝗼𝗹𝗹𝗼𝘄 𝘁𝗵𝗲 𝗹𝗶𝗻𝗸 𝗯𝗲𝗹𝗼𝘄.   Judith Charpentier Olivier Lieven Tobias Nordblom Maddie Yudkin Clémence Kopff Joyce Zhou Paola Gentilini Laura Kichenside Parinaz Bhot Wil Boren Jimmy D. Yutaka Yamaguchi Tim Mullane    #Healthcare #Medtech #BusinessExpansion #Innovation #Fertility